Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We developed a model for the translocation of intraluminal endotoxin in the neonatal animal and used it to examine the capacity of a nonhepatotoxic bile acid, ursodeoxycholic acid (UDCA), to modify endotoxin translocation and cytokine response. Three-d-old Sprague-Dawley rats were randomized to receive enterally either no drug, lipopolysaccharide (LPS, 1 mg/animal), or UDCA (400 μg/animal) alone, or UDCA followed by LPS 1 h later. One h after LPS administration, the rats were killed and plasma endotoxin and tumor necrosis factor (TNF) were measured. Control animals had low circulating endotoxin (21.2 ± 7.6 endotoxin units) and TNF (0.06 ± 0.02 ng/mL). Enteral administration of LPS 1 h before the rats were killed resulted in significant elevation of endotoxin (249.5 ± 71.3, p = 0.008) and TNF (3.6 ± 1.3, p = 0.019). UDCA alone did not alter endotoxin levels (8.7 ± 2.1). UDCA 1 h before LPS prevented the rise in endotoxin (38.9 ±11.2 endotoxin units) and TNF (0.2 ± 0.05) significantly. Chenodeoxycholic acid was studied in a similar group of experiments and prevented neither the translocation of LPS nor the development of increased TNF levels in animals receiving LPS. In conclusion, LPS can cross the intestinal barrier in the normal neonatal rat. UDCA, administered before LPS, can decrease the translocation of LPS and prevent the cytokine response as measured by TNF levels. We speculate that UDCA, administered prophylactically, might reduce morbidity in clinical conditions leading to gut-derived endotoxemia.

Original languageEnglish (US)
Pages (from-to)214-217
Number of pages4
JournalPediatric Research
Volume35
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Ursodeoxycholic Acid
Endotoxemia
Endotoxins
Tumor Necrosis Factor-alpha
Cytokines
Newborn Animals
Chenodeoxycholic Acid
Bile Acids and Salts
Small Intestine
Sprague Dawley Rats
Lipopolysaccharides
Morbidity

Cite this

Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. / Schwarzenberg, Sarah J; Bundy, Mary.

In: Pediatric Research, Vol. 35, No. 2, 01.01.1994, p. 214-217.

Research output: Contribution to journalArticle

@article{360a3ca88c914480bf2413bf0ca4e134,
title = "Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats",
abstract = "We developed a model for the translocation of intraluminal endotoxin in the neonatal animal and used it to examine the capacity of a nonhepatotoxic bile acid, ursodeoxycholic acid (UDCA), to modify endotoxin translocation and cytokine response. Three-d-old Sprague-Dawley rats were randomized to receive enterally either no drug, lipopolysaccharide (LPS, 1 mg/animal), or UDCA (400 μg/animal) alone, or UDCA followed by LPS 1 h later. One h after LPS administration, the rats were killed and plasma endotoxin and tumor necrosis factor (TNF) were measured. Control animals had low circulating endotoxin (21.2 ± 7.6 endotoxin units) and TNF (0.06 ± 0.02 ng/mL). Enteral administration of LPS 1 h before the rats were killed resulted in significant elevation of endotoxin (249.5 ± 71.3, p = 0.008) and TNF (3.6 ± 1.3, p = 0.019). UDCA alone did not alter endotoxin levels (8.7 ± 2.1). UDCA 1 h before LPS prevented the rise in endotoxin (38.9 ±11.2 endotoxin units) and TNF (0.2 ± 0.05) significantly. Chenodeoxycholic acid was studied in a similar group of experiments and prevented neither the translocation of LPS nor the development of increased TNF levels in animals receiving LPS. In conclusion, LPS can cross the intestinal barrier in the normal neonatal rat. UDCA, administered before LPS, can decrease the translocation of LPS and prevent the cytokine response as measured by TNF levels. We speculate that UDCA, administered prophylactically, might reduce morbidity in clinical conditions leading to gut-derived endotoxemia.",
author = "Schwarzenberg, {Sarah J} and Mary Bundy",
year = "1994",
month = "1",
day = "1",
doi = "10.1203/00006450-199402000-00018",
language = "English (US)",
volume = "35",
pages = "214--217",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats

AU - Schwarzenberg, Sarah J

AU - Bundy, Mary

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We developed a model for the translocation of intraluminal endotoxin in the neonatal animal and used it to examine the capacity of a nonhepatotoxic bile acid, ursodeoxycholic acid (UDCA), to modify endotoxin translocation and cytokine response. Three-d-old Sprague-Dawley rats were randomized to receive enterally either no drug, lipopolysaccharide (LPS, 1 mg/animal), or UDCA (400 μg/animal) alone, or UDCA followed by LPS 1 h later. One h after LPS administration, the rats were killed and plasma endotoxin and tumor necrosis factor (TNF) were measured. Control animals had low circulating endotoxin (21.2 ± 7.6 endotoxin units) and TNF (0.06 ± 0.02 ng/mL). Enteral administration of LPS 1 h before the rats were killed resulted in significant elevation of endotoxin (249.5 ± 71.3, p = 0.008) and TNF (3.6 ± 1.3, p = 0.019). UDCA alone did not alter endotoxin levels (8.7 ± 2.1). UDCA 1 h before LPS prevented the rise in endotoxin (38.9 ±11.2 endotoxin units) and TNF (0.2 ± 0.05) significantly. Chenodeoxycholic acid was studied in a similar group of experiments and prevented neither the translocation of LPS nor the development of increased TNF levels in animals receiving LPS. In conclusion, LPS can cross the intestinal barrier in the normal neonatal rat. UDCA, administered before LPS, can decrease the translocation of LPS and prevent the cytokine response as measured by TNF levels. We speculate that UDCA, administered prophylactically, might reduce morbidity in clinical conditions leading to gut-derived endotoxemia.

AB - We developed a model for the translocation of intraluminal endotoxin in the neonatal animal and used it to examine the capacity of a nonhepatotoxic bile acid, ursodeoxycholic acid (UDCA), to modify endotoxin translocation and cytokine response. Three-d-old Sprague-Dawley rats were randomized to receive enterally either no drug, lipopolysaccharide (LPS, 1 mg/animal), or UDCA (400 μg/animal) alone, or UDCA followed by LPS 1 h later. One h after LPS administration, the rats were killed and plasma endotoxin and tumor necrosis factor (TNF) were measured. Control animals had low circulating endotoxin (21.2 ± 7.6 endotoxin units) and TNF (0.06 ± 0.02 ng/mL). Enteral administration of LPS 1 h before the rats were killed resulted in significant elevation of endotoxin (249.5 ± 71.3, p = 0.008) and TNF (3.6 ± 1.3, p = 0.019). UDCA alone did not alter endotoxin levels (8.7 ± 2.1). UDCA 1 h before LPS prevented the rise in endotoxin (38.9 ±11.2 endotoxin units) and TNF (0.2 ± 0.05) significantly. Chenodeoxycholic acid was studied in a similar group of experiments and prevented neither the translocation of LPS nor the development of increased TNF levels in animals receiving LPS. In conclusion, LPS can cross the intestinal barrier in the normal neonatal rat. UDCA, administered before LPS, can decrease the translocation of LPS and prevent the cytokine response as measured by TNF levels. We speculate that UDCA, administered prophylactically, might reduce morbidity in clinical conditions leading to gut-derived endotoxemia.

UR - http://www.scopus.com/inward/record.url?scp=0028091402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028091402&partnerID=8YFLogxK

U2 - 10.1203/00006450-199402000-00018

DO - 10.1203/00006450-199402000-00018

M3 - Article

C2 - 8165057

AN - SCOPUS:0028091402

VL - 35

SP - 214

EP - 217

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 2

ER -